Back to results
US 2023/0399321 A1Published application
Crystalline form ii of melanocortin receptor agonist compound and preparation method therefor
AssigneeLG Chem, Ltd.
InventorsJin Ok HAM, Ho Yeon LEE, Ji Yoon KIM, Sung Won KIM, Seul Ah CHUN, Sang Dae LEE, Jong Won PARK
Life of this patent
Estimating the term…
Abstract
The present invention relates to a crystalline form II represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form II represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.
Claims13
A crystalline form II of a compound of the following formula 1, a pharmaceutically acceptable salt thereof, or a solvate thereof,
- wherein the X-ray powder diffraction pattern has 3 or more characteristic peaks selected from among peaks with the following diffraction angles (2θ values) of:
- 7.77±0.2°, 9.82±0.2°, 10.50±0.2°, 11.37±0.2°, 12.36±0.2°, 15.17±0.2°, 15.46±0.2°, 15.88±0.2°, 16.75±0.2°, 17.59±0.2°, 17.93±0.2°, 18.33±0.2°, 19.64±0.2°, 20.19±0.2°, 21.19±0.2°, 21.71±0.2°, 23.29±0.2°, 23.58±0.2°, 24.42±0.2°, 25.07±0.2°, 25.63±0.2°, 26.31±0.2°, 27.17±0.2°, 27.52±0.2°, and 28.96±0.2°:
- wherein R1 is C2-C5 alkyl.
Dependencies are inferred from the claim text.